Dose proportionality of reboxetine enantiomers in healthy male volunteers

Biopharmaceutics and Drug Disposition

Volumn 20, Issue 4, 1999, Pages 177-181

  Rey, E ^a   Dostert, P ^b   D'Athis, Ph ^a   Jannuzzo, M G ^b   Poggesi, I ^b   Olive, G ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

^b PFIZER INC   (United States)

Author keywords

Antidepressant; Enantiomers; Pharmacokinetics

Indexed keywords

ANTIDEPRESSANT AGENT; REBOXETINE;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RACEMIC MIXTURE;

EID: 0032837837     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199905)20:4<177::AID-BDD172>3.0.CO;2-I     Document Type: Article

References (14)

1. Riva M, Brunello N, Rovescalli AC, Galimberti R, Carfagna N, Carminati P, Pozzi O, Ricciardli S, Roncucci R, Rossi A, Racagni G. Effect of reboxetine, a new antidepressant drug, on the central noradrenergic system: behavioural and biochemical studies. J Drug Dev 1989; 1: 243-253.
2. Melloni P, Della Torre A, Lazzari E, Mazzini G, Meroni M. Configurational studies on 2-(α-(2-ethoxyphenoxy) benzyl) morpholine FCE 20124. Tetrahedron 1985; 41: 1393-1399.
3. Strolin Benedetti M, Pellizzoni C, Poggesi I, Dostert P, Dubini A, Bosc M, Le Coz F, Cini M. Pharmacokinetics of reboxetine enantiomers in healthy volunteers. XIIth international Congress of Pharmacology. Montreal, Canada July 24-29, 1994, Abstract.
4. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997; 7: S23-S35.
5. Strolin Benedetti M, Frigerio E, Tocchetti P, Brianceschi G, Castelli MG, Pellizoni C, Dostert P. Stereoselective and species-dependent kinetics of reboxetine in mouse and rat. Chirality 1995; 7: 285-289.
6. Edwards DMF, Pellizzoni C, Breuel HP, Berardi A, Castelli MG, Frigerio E, Poggesi I, Rocchetti M, Dubini A, Strolin Benedetti M. Pharmacokinetics of reboxetine in healthy volunteers. Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995; 16: 443-460.
7. Frigerio FE, Pianezzola E, Strolin Benedetti M. Sensitive procedure for the determination of reboxetine enantiomers in human plasma by reversed-phase high-performance liquid chromatography with fluorimetric detection after chiral derivatization with (+)-1-(9-fluorenyl) ethyl chloroformate. J Chromatogr 1994; A. 660: 351-358.
8. Gibaldi M, Ferner D. Pharmacokinetics, 2nd edn. New York: Marcel Dekker, 1982.
9. Gex-Fabry M, Balant LP. Considerations on data analysis using computer methods and currently available software for personal computers. In: PG Welling, Balant LP (eds) Handbook of Experimental Pharmacology, Vol. 110; Pharmacokinetics of Drugs. Berlin Heidelberg: Springer-Verlag, 1994.
10. Boyd RA, Chin SK, Don-Pedro O, Williams RL, Giacomino KM. The pharmacokinetics of the enantiomers of atenolol. Clin Pharmacol Ther 1989; 45: 403-410.
11. Haegele KD, Schechter PJ. Kinetics of the enantiomers of vigabatrin after an oral dose of the racemate or the active S-enantiomer. Clin Pharmacol Ther 1986; 40: 581-586.
12. Wade DN, Mearrick PT, Mornis J. Active transport of L-Dopa in the intestine. Nature 1973; 242: 463-465.
13. Williams K, Lee E. Importance of drug enantiomers in clinical pharmacology. Drugs 1985; 30: 333-354.
14. Cocchiara G, Battaglia R, Pevarello P, Strolin Benedetti M. Comparison of the disposition and of the metabolic pattern of reboxetine, a new antidepressant, in the rat, dog, monkey and man. Eur J Drug Metab Pharmacokinet 1991; 16: 231-239.